**A**

**B**

**C**

**D**

**E**

**F**

**G**

**H**

**Supplementary Figure 1. Progression of metabolic deficits in DIO-NASH mice.** \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 (vs. week 0).

****

**Supplementary Figure 2. Histomorphological effects of liraglutide, obeticholic acid (OCA), and elafibranor treatment in DIO-NASH mice.** Individual steatosis, inflammation and ballooning scores. \*p<0.05, \*\*\*p<0.001 (vs. vehicle controls).

****

**Supplementary Figure 3. Histomorphological effects of liraglutide, obeticholic acid (OCA), and elafibranor in *ob/ob*-NASH mice.** Individual steatosis, inflammation and ballooning scores. \*\*p<0.01, \*\*\*p<0.001 (vs. vehicle controls).